LUCDNasdaq

Lucid Diagnostics Inc.

Healthcare·Oncology·Commercial·New York, NY, United States
OncologyRare DiseaseRespiratory

Lucid Diagnostics Inc. (LUCD): 1 pipeline candidate · 6 clinical trials. Updated within the last hour.

6.2/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health5.0

D/E 7.52 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider Signal6.5

1 buy · 0 sells (180d)

A transparent, data-derived signal for Lucid Diagnostics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$194.6M

Cash

Quarterly Burn

$12.1M

Runway

Revenue

$1.3M

Pipeline (1 candidate)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

100

Total value held

$39.6M

HolderSharesValue
vanguard capital management llc8,309,540$9.6M
blackrock, inc.4,638,243$5.3M
masters capital management llc4,000,000$4.6M
two seas capital lp3,000,000$3.5M
geode capital management, llc2,245,350$2.6M
state street corp1,554,581$1.8M
wells fargo & company/mn1,274,390$1.5M
perkins capital management inc1,126,000$1.3M
sunbelt securities, inc.900,013$1.0M
northern trust corp670,585$771K

Showing top 10 of 100 institutional holders of Lucid Diagnostics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

6 clinical trials·CEO: Dr. Lishan Aklog M.D.

Frequently asked questions

How many drug candidates are in Lucid Diagnostics Inc.'s pipeline?

Lucid Diagnostics Inc. (LUCD) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is Lucid Diagnostics Inc.'s lead drug candidate?

Lucid Diagnostics Inc.'s most advanced tracked candidate is esoguard (Approved) for Barrett's Esophagus (BE) and esophageal adenocarcinoma (EAC).

What is Lucid Diagnostics Inc.'s market capitalization?

Lucid Diagnostics Inc.'s market capitalization is approximately $194.6M.

Who is the CEO of Lucid Diagnostics Inc.?

Dr. Lishan Aklog M.D. is the chief executive officer of Lucid Diagnostics Inc. (LUCD).

Get the full picture on Lucid Diagnostics Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.